Invention Grant
- Patent Title: Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
-
Application No.: US17475305Application Date: 2021-09-14
-
Publication No.: US11884919B2Publication Date: 2024-01-30
- Inventor: Antonin de Fougerolles , Tatiana Novobrantseva , Gregory Hinkle
- Applicant: Alnylam Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Womble Bond Dickinson (US) LLP
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C12N15/113 ; A61K31/713
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
Public/Granted literature
- US20220243199A1 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE Public/Granted day:2022-08-04
Information query
